Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence

Deuk Yong Lee, Dong-Yun Lee, Lee DY, D-S Bae, Duk-Soo Bae, Bae DS, Yoon BK, Byung-Koo Yoon, Dukhyun Choi, DooSeok Choi, Choi D
Human Reproduction · 2010 · vol. 25(12) , pp. 3050–3054 · doi:10.1093/humrep/deq279 · PMID:20937741 · W2124643065
Observational OA: bronze CC0 ⤵ 48 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Post-operative cyclic oral contraceptive use following GnRH agonist treatment was found to significantly reduce endometrioma recurrence compared to GnRH agonist treatment alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Currently, no standard post-operative medical therapy has been shown to be superior in reducing the recurrence of endometrioma. This retrospective study was performed to evaluate the efficacy of post-operative cyclic oral contraceptive (OC) use after GnRH agonist (GnRHa) treatment for the prevention of endometrioma recurrence. METHODS: This retrospective study included 362 reproductive-aged patients who had undergone pelviscopic surgery for endometrioma. Patients were divided into two groups: a group that received cyclic, low-dose, monophasic OCs after GnRHa treatment (n = 175) and a group that received only GnRHa treatment (n = 187). Endometrioma recurrence was evaluated by an ultrasound. RESULTS: During the follow-up period (median, 35 months; range, 12-114 months), recurrent endometriomas were detected in 67 patients (18.5%). Patients receiving cyclic OCs after GnRHa treatment showed a significantly reduced recurrence risk of endometrioma, when compared with patients receiving GnRHa alone (odds ratio = 0.20; 95% confidence interval, 0.10-0.38). The cumulative proportion of recurrent endometrioma after 60 months was significantly lower in OC users than in non-users (6.1 versus 43.3%; P < 0.001), and a statistically significant difference was first detected at 30 months of follow-up (5.1 versus 17.1%; P = 0.018). The number of GnRHa injections (3 versus 6) did not affect the recurrence rate for up to 60 months in OC non-users or users. CONCLUSIONS: Post-operative cyclic OC use after GnRHa treatment effectively reduces the recurrence of endometrioma.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Contraceptives, Oral, Combined Endometriosis Gonadotropin-Releasing Hormone Contraceptives, Oral, Combined Contraceptives, Oral, Combined Endometriosis Endometriosis Endometriosis Endometriosis Female Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Humans Postoperative Period Postoperative Period Retrospective Studies Retrospective Studies

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (21)

Cited by (48)

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:04.945943+00:00
License: CC0 · commercial use OK